MicroVue™ CH50 Eq EIA

The MicroVue CH50 Eq EIA measures the total classical complement pathway activity in human serum and allows detection of a deficiency of one or more of the complement components C1 through C9.


Product Specifications

Citations 17
Specimen

Serum 14 μL

LLOQ N/A
ULOQ N/A
Assay Time 3.5 hours
Cross Reactivity

Cynomolgous monkey

Ordering Information

For In Vitro Diagnostic Use.
Catalog Number A018
Catalog Number (CE)  
Size 96 wells/test
Price (USD) $725.00
Price (EURO) 640,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

The MicroVue CH50 Eq EIA measures the total classical complement pathway activity in human serum and allows detection of a deficiency of one or more of the complement components C1 through C9.

Size 96 wells/test
Form

96 well plate with 12 eight-well strips in a resealable foil pouch

Specimen Serum 14 μL
Limit of Detection (LOD) N/A
Lower Limit of Quantitation (LLOQ) N/A
Upper Limit of Quantitation (ULOQ) N/A
Intra Assay 3.2–4.5%
Inter Assay 5.4–8.7%
Standards 5
Controls 2
Sample Values

Normal 133±54 CH50 U Eq/mL

Assay Time 3.5 hours
Cross Reactivity

Cynomolgous monkey

Storage

Store the unopened kit at 2°C to 8°C. Refer to Product Insert for additional storage details.

Background

The binding of C1q component of C1 to immune complexes triggers the classical complement pathway. This activation results in a cascade of enzymatic and non-enzymatic reactions, culminating in the formation of terminal complement complexes (TCC). Under standard conditions the level of TCC that can be generated in a serum is a quantitative expression of the serum’s total classical complement activity. The traditional method for measuring the total classical complement activity in serum is the CH50 test. This test is a lytic assay, which uses antibody-sensitized sheep erythrocytes (EA) as the activator of the classical complement pathway and various dilutions of the test serum to determine the amount required to give 50% lysis. The percent hemolysis is determined spectrophotometrically. The CH50 test is an indirect measure of TCC, since the TCC themselves are directly responsible for the hemolysis that is measured. The MicroVue CH50 Eq EIA provides a direct measure of the total classical complement activity in serum by quantifying the amount of TCC generated under standard conditions. The MicroVue CH50 Eq EIA uses a monoclonal antibody to a unique neoantigen to capture the TCC analyte. Since both the CH50 Eq EIA and the CH50 test rely on the generation of TCC and correlate, the CH50 Eq EIA’s results are expressed in CH50 unit equivalents per milliliter.

Citations

Title Year Applications Sample Species Sample Sample Details

Decreased immune response in monkeys administered a human T-effector cell agonist (OX40) antibody.

2020

ELISA

Cynomolgus Monkey

Plasma, Serum

T-effector cell agonist (OX40) antibody

Inhibition of aberrant complement activation by a dimer of acetylsalicylic acid.

2015

ELISA

Human

Serum

Acetyl salicylic acid dimer 5,5'-methylenebis(2-acetoxybenzoic acid) (DAS)

The endogenous neuronal complement inhibitor SRPX2 protects against complement-mediated synapse elimination during development.

2020

ELISA

Human

Serum

HEK 293 Cells incubated

The Immunologic Effect of Early Intravenous Two and Four Gram Bolus Dosing of Tranexamic Acid Compared to Placebo in Patients With Severe Traumatic Bleeding (TAMPITI): A Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial.

2020

ELISA

Human

Plasma

Severe Traumatic Bleeding

Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state.

2021

ELISA

Human

Serum

COVID-19

In Vitro Studies Regarding the Safety of Chitosan and Hyaluronic Acid-Based Nanohydrogels Containing Contrast Agents for Magnetic Resonance Imaging.

2022

ELISA

Human

Serum

Chitosan and Hyaluronic Acid-Based Nanohydrogels

Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study.

2022

ELISA

Human

Serum

COVID-19

Complement C3 serum levels in anorexia nervosa: a potential biomarker for the severity of disease

2011

ELISA

Human

Serum

Heightened measures of immune complex and complement function and immune complex-mediated granulocyte activation in human lymphatic filariasis

2011

ELISA

Human

Plasma

Lymphatic filariasis

Gene expression changes in human islets exposed to type 1 diabetic serum

2012

ELISA

Human

Serum

Islet Cells

Amblyomma americanum tick saliva serine protease inhibitor 6 is a cross-class inhibitor of serine proteases and papain-like cysteine proteases that delays plasma clotting and inhibits platelet aggregation

2013

ELISA

Human

Serum

AamS6 tick protein incubated

Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury

2013

ELISA

Human

Serum

OmCI tick protein incubated

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

2016

ELISA

Human

Serum

Host- and pathogen-derived adjuvant coatings on protein nanoparticle vaccines

2017

ELISA

Human

Serum

Nanoparticles incubated

Persistent complement dysregulation with signs of thromboinflammation in active Long Covid.

2023

ELISA

Human

Serum

COVID-19

Persistent complement dysregulation with signs of thromboinflammation in active Long Covid

2024

ELISA

Human

Serum

COVID-19

Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor

2010

ELISA

Human, Primate

Serum